Current therapies for Alzheimer’s disease (AD) primarily target tau and amyloid beta (Aβ) peptides and include inhibitors to reduce tau protein phosphorylation and BACE inhibitors to reduce Aβ levels. Aβ antibodies are also used to sequester free Aβ from plasma for clearance by the immune system. The development of effective AD therapies is very challenging and few compounds have shown significant benefits in clinical trials, primarily due to the lack of druggable targets and reliable biomarkers.
At Charles River, our scientists can guide you in the selection of the appropriate assay or disease model for every stage of the drug discovery process. Our extensive portfolio supports novel study designs and offers end-to-end validated in vitro services and in vivo models of pharmacology and toxicology. Our novel imaging modalities, behavioral tests and biomarker endpoint assays enable you to make effective decisions to help identify new therapies for Alzheimer’s disease.
Request information about AD capabilities »
We've included a list of our available capabilities and models below, and have answered some frequently asked questions about our Alzheimer’s disease models.